<DOC>
	<DOCNO>NCT00682643</DOCNO>
	<brief_summary>The purpose study ass long-term ocular safety fluticasone furoate nasal spray adult adolescent subject diagnose perennial allergic rhinitis .</brief_summary>
	<brief_title>A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial ( Year-round ) Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Subjects eligible enrollment study must meet following criterion : Informed consent Subject provide appropriately sign date informed consent . An appropriately sign dated assent must obtain parent guardian subject child 18 year age . Outpatient Subject treatable outpatient basis . Age 12 year age old Visit 2 Male eligible female Female subject enrol plan become pregnant time study participation . To eligible entry study , female childbearing potential must commit consistent correct use acceptable method birth control , define follow : Abstinence Females childbearing potential sexually active must commit complete abstinence intercourse two week exposure study drug , throughout clinical trial , period trial account elimination drug ( minimum six day ) . Oral contraceptive ( either combine estrogen/progestin progestin ) Injectable progestogen Implants levonorgestrel Percutaneous contraceptive patch Intrauterine device ( IUD ) intrauterine system ( IUS ) document failure rate le 1 % per year , Male partner sterile ( vasectomy documentation azoospermia ) prior female subject 's entry study sole sexual partner female subject , Double barrier methodcondom occlusive cap ( diaphragm cervical /vault cap ) plus Spermicide , Estrogenic vaginal ring . A urine pregnancy test do screen visit confirm females childbearing potential pregnant upon entry study . In addition , urine pregnancy test do female childbearing potential clinic visit . Diagnosis PAR include : A positive skin test ( prick method ) response appropriate perennial allergen ( house dust mite , animal dander , mold , cockroach ) within last 12 month prior Visit 1 Visit 1 . A positive skin test define wheal ³3mm large diluent control prick testing . •Two year medical history past treatment PAR ( write verbal confirmation ) include perennial , i.e. , yearround , symptom . PAR symptom could include nasal congestion , rhinorrhea , nasal itch sneeze . In vitro test specific IgE ( RAST , PRIST ) allow diagnosis PAR . NOTE : Subjects meet criterion also may seasonal allergic rhinitis ( SAR ) and/or perennial nonallergic rhinitis ( PNAR ) eligible randomization . Environment •Subject must symptomatic appropriate perennial allergen ( animal dander , house dust mite , cockroach , mold ) willing maintain , much possible , environment throughout study . Ability comply study procedure Subject understand willing , able likely comply study procedure restriction . Literate Subject must able read , comprehend , record information English Subjects meeting follow criterion must enrol study : Significant concomitant medical condition , define limited : A historical current evidence clinically significant uncontrolled disease body system ( e.g. , tuberculosis , psychological disorder , eczema ) . Significant defined disease , opinion investigator , would put safety subject risk study participation would confound interpretation study result disease/condition exacerbate study . History current diagnosis diabetes mellitus Uncontrolled hypertension ( i.e. , systolic blood pressure ³ 140mm Hg diastolic blood pressure ³ 90mm Hg ) A severe physical obstruction nose ( e.g. , deviated septum nasal polyp ) nasal septal perforation could affect deposition double blind intranasal study drug Nasal ( e.g. , nasal septum ) ocular injury/surgery last 6 month ( include LASIK eye surgery ) Asthma , exception mild intermittent asthma [ National Asthma Education Prevention Program ( NAEPP ) Guidelines Diagnosis Management Asthma Expert Panel Report 3 , National Institutes Health , August 28 , 2007 . NOTE : Subjects allow use shortacting inhaled beta2 agonists ONLY need basis . Rhinitis medicamentosa Bacterial viral infection ( e.g. , common cold ) eye upper respiratory tract within two week Visit 1 screening period Documented evidence acute significant chronic sinusitis , determine individual investigator Current history glaucoma and/or ocular herpes simplex Current cataract and/or previous history cataract surgery Physical impairment would affect subject 's ability participate safely fully study Clinical evidence Candida infection nose History psychiatric disease , intellectual deficiency , poor motivation , substance abuse ( include drug alcohol ) condition limit validity inform consent would confound interpretation study result History adrenal insufficiency History Hepatitis B C Use corticosteroid , define : Intranasal corticosteroid within 4 week prior Visit 1 ( e.g. , VERAMYST , FLONASE™ , Nasonex , Rhinocort ) . Inhaled , oral , intramuscular , intravenous , ocular , and/or topical corticosteroid ( exception topical hydrocortisone , 1 % less , equivalent ) within 8 week prior Visit 1 . Use allergy medication within timeframe indicated relative Visit 1 Intranasal ocular cromolyn within 14 day prior Visit 1 ( e.g. , Nasalcrom , Crolom ) Shortacting prescription nonprescription antihistamine , include ocular preparation antihistamine contain insomnia `` night time '' pain formulation , within 3 day prior Visit 1 ( e.g. , Benadryl , Chlortrimeton , Dimetane , Tavist ) Longacting antihistamine within 10 day prior Visit 1 ( e.g. , Allegra , Claritin , Clarinex , Zyrtec ) . Intranasal antihistamine ( e.g. , Astelin ) within 2 week prior Visit 1 Oral intranasal decongestant within 3 day prior Visit 1 ( e.g. , Sudafed ) Longacting betaagonists within 3 day prior Visit 1 ( e.g. , SEREVENT™ , Foradil ) Intranasal , oral , inhaled anticholinergic within 3 day prior Visit 1 ( e.g. , Atrovent ) Oral antileukotrienes within 3 day Visit 1 ( e.g. , Singulair ) Subcutaneous omalizumab ( Xolair ) within 5 month Visit 1 Use medication may affect allergic rhinitis symptom Chronic use concomitant medication , tricyclic antidepressant , would affect assessment effectiveness study drug Use intranasally administer medication ( e.g. , Miacalcin ) Use immunosuppressive medication 8 week prior screen study Immunotherapy Immunotherapy patient may enrol study immunotherapy initiate within 30 day Visit 1 , dose remain fixed 30 day prior Visit 1 , dose remain fixed duration study . Use medication significantly alter pharmacokinetics fluticasone furoate ( ritonavir ketoconazole ) Use chronic treatment agent know promote development cataract ( e.g. , potassiumsparing diuretic allopurinol ) Allergy/Intolerance Known hypersensitivity corticosteroid excipients Clinical trial/experimental medication experience Has recent exposure investigational study drug within 30 day Visit 1 Participation previous current FFNS ( GW685698X ) clinical study Positive urine pregnancy test female breastfeeding Has positive inconclusive pregnancy test Visit 1 Visit 2 Affiliation investigational site Subject participate investigator , subinvestigator , study coordinator , employee participate investigator , immediate family member aforementioned . Tobacco use Subject currently use smoking product include cigarette , cigar , pipe chew tobacco , use product last 6 month Chickenpox measles A subject eligible he/she currently chickenpox measles , expose chickenpox measles last three week nonimmune . If subject develop chickenpox measles study , he/she withdrawn study . If nonimmune subject expose chickenpox measles study , his/her continuation study discretion investigator , take consideration likelihood develop active disease . Findings clinically significant , abnormal ECG Findings clinically significant laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Perennial Allergic Rhinitis</keyword>
	<keyword>fluticasone furoate</keyword>
	<keyword>ocular safety</keyword>
</DOC>